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1 Drug description 
Generic/Brand name/ATC code:  
Crizotinib/Xalkori®/L01XE16 
Developer/Company:  
Pfizer Inc. 
Description:  
Crizotinib is a selective adenosine triphosphatase (ATP)-competitive small-
molecule inhibitor of the anaplastic lymphoma kinase (ALK) and the c-Met/ 
hepatocyte growth factor receptor (HGFR) with antineoplastic activity there-
fore inhibiting tumour cell growth [1]. The echinoderm microtubule-associ-
ated protein-like 4 (EML4)-ALK fusion gene is responsible for the for-
mation of non-small lung cancer (NSCLC) in some cases. 
For the identification of patients eligible for treatment with crizotinib ALK-
testing is necessary using an accurate and validated assay.  
The recommended dose schedule of crizotinib is 500 mg daily (250 mg bid) 
administered orally. The treatment should be continued until disease pro-
gression or unacceptable toxicity [2].  
 
 
2 Indication 
Patients with advanced NSCLC harboring a translocation or inversion event 
involving the ALK gene locus.  
 
 
3 Current regulatory status 
In October 2012, the European Commission (EC) granted a conditional mar-
keting authorisation for crizotinib for the treatment of adults with previ-
ously treated anaplastic lymphoma kinase (ALK)-positive advanced NSCLC 
[2-5]. The authorisation followed the recommendation of the Committee for 
Medicinal Products for Human Use (CHMP) that considered by consensus 
the risk-benefit balance of Xalkori® for this indication to be favourable [5]. 
The conditional marketing authorisation requires the marketing authorisa-
tion holder to provide additional data in the future.  
crizotinib inhibits  
ALK and HGFR 
ALK-testing is necessary 
tablets for oral 
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patients with  
ALK-positive NSCLC 
EMA: treatment of 
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treated ALK-positive 
advanced NSCLC 
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In August 2011, the U.S. Food and Drug Administration (FDA) approved 
crizotinib for the orphan indication „treatment of patients with locally ad-
vanced or metastatic NSCLC that is ALK-positive as detected by an FDA-
approved test” [1, 6, 7]. This authorisation was not restricted to previously 
treated adult patients. The indication was based on the response rate re-
ported in two clinical trials (phase I and phase II) without data demonstrat-
ing improvement in patient reported outcomes or survival. The approval was 
issued under the provisions of accelerated approval regulations of new drugs 
for serious or life-threatening illnesses. Its granting is contingent upon com-
pletion of postmarketing clinical trials (phase III) to verify and describe the 
clinical benefit. 
Recently, crizotinib also obtained orphan drug designations from the FDA 
for the treatment of anaplastic large cell lymphoma (28 Nov 2012) and neuro-
blastoma (31 Oct 2012) [7, 8]. 
 
 
4 Burden of disease 
Lung cancer is the leading cause of tumour related mortality worldwide 
(2.4 %) and even more pronounced in the European region (4.1 %), with 
69 % and 75 % of the deaths affecting men, respectively [9]. Worldwide, the 
age standardized incidence rates (per 100,000 population) were estimated to 
be 33.8 and 13.5 for men and women respectively, and mortality rates 29.2 
and 10.9. Accordingly, for lung cancer in the European Region the incidence 
rates for men and women were 48.1 and 12.7, and the mortality rates 42.0 and 
10.3, respectively [10]. The median age at diagnosis for cancer of the lung 
and bronchus is 70 years [11]. 
Various risk factors are associated with lung cancer, tobacco smoking being 
the most important and accounting for about 90 % of all lung cancers [12]. 
Both the amount of daily smoked cigarettes and the lifetime duration of smok-
ing increase the risk, while it decreases again when smoking is ceased [13]. 
Besides exposure to tobacco smoke additional environmental factors like ra-
don, asbestos (particularly among smokers), arsenic or ionising radiation are 
known to increase the risk to develop lung cancer and also a genetic predis-
position, pulmonary fibrosis and HIV infection may affect the risk for this 
disease [12]. 
Usually lung cancer is asymptomatic particularly during early stage disease. 
Therefore it is often diagnosed at advanced stages resulting in a poor prog-
nosis [14]. Among the wide range of possible symptoms cough, haemoptysis, 
dyspnoea, and chest pain are the most common. Other symptoms may occur 
due to nerve damages (e.g. unilateral paralysis of the diaphragm, Pancoast’s 
syndrome) or metastases that most frequently spread to the liver, bone, brain 
and adrenal glands [12]. 
Generally, one can differentiate between small-cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC) [12]. About 85 % of all lung cancers be-
long to NSCLC which can be differentiated further into 2 types: non-squamous 
carcinoma and squamous cell carcinoma [15]. 
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Based on the tumour node metastasis (TNM) staging system for NSCLC de-
veloped by the International Association for the Study of Lung Cancer (IASLC) 
four disease stages (stage I, II, III and IV) can be determined [16]. 
For this the primary tumour characteristics, the presence or absence of re-
gional lymph node involvement and distant metastases are taken into ac-
count. Advanced NSCLC describes a situation, where only systemic treat-
ment is indicated. It comprises disease stage IIIB and stage IV including 
M1a (formerly partly also described as stage IIIB) with malignant pleural or 
pericardial effusion, pleural nodules, metastatic nodules in the contralateral 
lung and M1b, distant metastases. 
In patients with advanced disease, performance status is used to estimate pa-
tients’ prognosis and to establish a treatment plan. Early-stage disease, good 
performance status (ECOG PS 0, 1 or 2), absence of significant weight loss 
(not more than 5 %) and female gender are the most important prognostic 
factors regarding the prediction of survival of NSCLC patients. Age and his-
tological subtypes do not play a major role in prognosis of tumour develop-
ment [15] but in choice of treatment modalities and chemotherapeutic agents. 
Activating mutations of the epidermal growth factor receptor (EGFR) gene 
have a major impact on the level of response to tyrosine kinase inhibitors 
[17]. In addition to these EGFR mutations, other genetic alterations have 
been identified as oncogenic drivers in the pathogenesis of NSCLC, espe-
cially adenocarcinoma. In 2007, it was reported that a small inversion within 
chromosome 2p results in the formation of a fusion gene comprising por-
tions of the EML4 gene and ALK in NSCLC cells [18]. 
The EML4-ALK fusion gene is responsible for only 1-7 % of NSCLC. ALK-
positive NSCLC are found in patients of all ages, although on average these 
patients are relatively younger than those without this abnormality. These 
types of NSCLC are also more common in light cigarette smokers or non-
smokers, but a significant number of patients with this disease are current or 
former cigarette smokers [19]. 
Diagnostic approaches to detect ALK rearrangements include immunohisto-
chemistry (IHC), fluorescence in situ hybridization (FISH) and reverse tran-
scriptase polymerase chain reaction (RT-PCR) [20]. Currently, the only clini-
cally validated test to determine ALK status is the Vysis/Abbott ALK FISH 
break apart test, which is also approved by the FDA [1]. 
In Austria, lung tumours account for more than 11 % of all malignant neo-
plasms and are the leading cause of cancer deaths in males. Within the last 
20 years about 3,400 to 4,300 patients were newly diagnosed with lung can-
cer each year, while the number of people dying of this disease was about 
10 % to 15 % lower [21]. Men are more often affected than women (in 2009: 
2,747 men vs. 1,492 women; 42.2 vs. 19.5 per 100,000 habitants, respectively), 
but in recent years the incidence and mortality rates have decreased in men 
while they have increased in women. More than 80 % of the tumours histo-
logically classified as carcinomas were NSCLCs [21]. 
Applying the above mentioned estimates approximately 30 to 200 patients 
will be newly diagnosed with ALK-positive NSCLC per year in Austria. For 
that, many more patients (about 2,900 diagnosed with NSCLC [21]) will have 
to be assessed with the ALK assay. 
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5 Current treatment 
Surgery, radiation therapy and chemotherapy, targeted therapy and best sup-
portive care are the modalities commonly used for the treatment of NSCLC. 
Depending on the disease status, ECOG performance status and prognostic 
factors these treatments can be used either alone or in combination [22]. Pa-
tients with early stage disease are treated with surgery, whereas individuals 
with locally advanced disease are either treated with radiotherapy alone or 
in combination with chemotherapy, and neo-adjuvant approaches. Patients 
with advanced disease and good prognosis (ECOG PS 0 to 1) are treated with 
double-agent chemotherapy or targeted therapy, whereas patients with poor 
prognosis (ECOG PS 2 to 4) receive single-agent chemotherapy, targeted ther-
apy or best supportive care [14, 15].  
According to the NCCN Guidelines the current standards of treatment as 
first line therapy in patients with advanced NSCLC [15, 19] are: 
 a double agent chemotherapy regimen, consisting of one plati-
num-based agent (cisplatin, carboplatin) in combination with a sec-
ond agent (paclitaxel, gemcitabine, vinorelbine or docetaxel and 
pemetrexed in patients with nonsquamous histology)  
 chemotherapy in combination with targeted therapeutic agent 
(bevacizumab)  
 for patients with discovered EGFR mutation, erlotinib (and in Eu-
rope also gefitinib) is indicated as first line therapy.  
 for maintenance therapy, treatment options for patients with stable 
disease or tumour response include [19]: 
 the continuation with a single agent targeted therapy   
(e.g. bevacizumab) 
 the continuation with a single agent chemotherapy   
(e.g. pemetrexed, gemcitabine) 
 a switch to erlotinib or pemetrexed. 
As second line therapy the following treatments are recommended: 
 single agent chemotherapy (docetaxel or pemetrexed) 
 targeted agent therapy (e.g. erlotinib) 
 a platinum based combination therapy for patients with EGFR mu-
tation and progressive disease after tyrosine kinase inhibitor treat-
ment (e.g. erlotinib)  
For ALK-positive NSCLC patients the targeted agent crizotinib is the cur-
rently recommended treatment option as first or second line therapy [15, 19]. 
Chemotherapy is an appropriate option for these patients with disease pro-
gression on crizotinib. As patients with the ALK fusion oncogene do not ap-
pear to respond to EGFR tyrosine kinase inhibitors, erlotinib therapy is not 
recommended [19].  
 
 
 
 
choice of treatment 
depends on cancer 
stage, ECOG 
performance status 
first line therapy 
maintenan
ce therapy 
second line therapy 
for ALK-positive NSCLC: 
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6 Evidence 
To identify relevant primary and secondary literature, a systematic literature 
search was conducted on the 30th of November 2012 in the medical databases 
Ovid MEDLINE/Pubmed, EMBASE, the Cochrane Library and the CRD 
database yielding 379 records after removal of duplicates. Of those, 9 records 
reporting results of 2 single-arm phase I/II trials, were included [23-31]. 
Also a hand search was performed which included reference lists of topic-
related reviews or articles, a free web-search and the websites of the EMA 
and the FDA. This search resulted in the inclusion of 3 further publications 
[32-34], one of them reporting interim results of an ongoing phase III trial. 
Among the material that the manufacturer had sent on request, 8 additional 
conference papers on the already identified trials including one oral presen-
tation were retrieved [19, 24, 32, 33, 35-38].  
In summary 3 full text publications and 17 conference abstracts or presenta-
tions reporting on one phase III trial [19, 34] and 2 single arm phase I/II tri-
als [19, 23-28, 31-39] were included. 
 
 
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
STUDY TITLE  
Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of 
care chemotherapy (pemetrexed or docetaxel) in patients with non-small lung cancer harboring a 
translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus  
(Profile 1007) [19, 34]. 
Study  
identifier 
NCT 00932893  
EudraCT 2009-012595-27 
Design Randomized controlled, parallel, open-label, international, multi-centre trial;  
N = 347 (173 vs. 174); 
allocation randomly to crizotinib or chemotherapy (pemetrexed or docetaxel); 
Investigator selection of either pemetrexed or docetaxel as the active comparator; 
Duration  Enrolment: February 2010 to February 2012 
Median follow-up:  
 Crizotinib: 12.2 months (11.0−13.4) 
 Chemotherapy: 12.1 months (10.6−13.6) 
 Cut-off date for final analysis: March 2012 
Hypothesis Superiority 
Funding Pfizer Inc. 
Treatment 
groups 
Intervention Crizotinib 250 mg bid PO, 21-day cycle 
Control Pemetrexed, 500 mg/m2, iv infusion over 10 minutes  
on Day 1 of each 21-day cycle or 
Docetaxel, 75 mg/m2, iv infusion over 1 hour  
on Day 1 of each 21-day cycle 
all ongoing:  
one phase III trial and 
two phase I/II trials for 
ALK-positive NSCLC 
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Endpoints 
and 
definitions 
Progression-free survival 
(primary outcome) 
PFS Time from random assignment to first progressive 
disease or death. PFS was detected per independent 
radiology review (according to RECIST version 
1.1). 
Objective response rate 
(secondary outcome) 
ORR NR 
Duration of response 
(secondary outcome) 
DR NR 
Disease control rate 
(secondary outcome) 
DCR NR 
Overall survival 
(secondary outcome) 
OS NR 
Safety  
(secondary outcome) 
S  NR 
Symptoms of lung cancer 
(secondary outcome) 
Sym Patient self-reported (cough, dyspnea, fatigue, 
alopecia, insomnia and pain); 
Time to Deterioration in 
Lung Cancer Symptoms 
TDSym Patient self-reported; Composite endpoint of pain, 
cough, dyspnea; 
Health-related quality of 
life (secondary outcome) 
HrQoL Patient self-reported; EORTC QLQ-C30 and  
QLQ-LC-13 were used for evaluation; 
RESULTS AND ANALYSIS 
Analysis  
description 
ITT-analysis 
Primary endpoint: PFS per independent radiology review – sample size: 217 events 
(progressive disease or death) are needed to detect a hazard ratio of 0.64 (or increase in 
median PFS from 4.5 to 7 months) at one-sided 2.5 % significance level with 90 % 
power 
Secondary endpoint: OS – pre-specified interim OS analysis at time of final PFS 
analysis; 80 % power to detect 44 % increase in OS when 241 deaths occur 
Analysis  
population 
Inclusion  histologically or cytologically proven diagnosis of NSCLC (Stage IIIB/IV); 
positive for the ALK fusion gene (test provided by a central laboratory); 
disease progression after only one prior chemotherapy (regimen 
must have included one platinum drug); measurable tumours; 
ECOG performance status 0-2; 
Exclusion prior treatment with crizotinib (PF-02341066); 
current treatment in another clinical trial; 
Characteristics 347 patients with ALK-positive Stage IIIB/IV NSCLC who had 
received one prior chemotherapy (platinum-based). 
Control (n=174) vs. Intervention (n=173): 
Median age (years): 49 (24-85) vs. 51 (22-81) 
Female (%): 55 vs. 57 
Ethnicity Caucasian/Asian/Others (%): 52/45/3 vs. 52/46/2 
Never smoker (%): 64 vs. 62 
Ex-Smoker (%): 31 vs. 34 
Current smoker (%): 5 vs. 3 
Adenocarcinoma (%): 94 vs. 95 
ECOG performance status 0/1/2 (%): 37/55/8 vs. 42/49/9 
Brain metastases (%): 35 vs. 35 
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Results 
(interim 
analysis  
12 mo f/up)  
Treatment group Chemotherapy  
(pemetrexed or docetaxel) 
Crizotinib 
Number of subjects 174 173 
PFS (months)  
median 
95 % CI 
 
3.0 
NR 
 
7.7 
NR 
ORR (%)  
median 
95 % CI 
 
19.5 
NR 
 
65.3 
NR 
OS (months)  
median 
95 % CI 
 
22.8 
NR 
 
20.3 
NR 
Sym NR NR 
HrQoL NR NR 
Number of subjects 151 162 
TDSym (months)  
median 
95 % CI 
 
1.4 
NR 
 
5.6 
NR 
Effect estimate 
per comparison 
(interim 
analysis  
12 mo f/up) 
Comparison groups  Intervention vs. Control 
PFS HR 0.49 
95 % CI 0.37 – 0.64 
P value  < 0.0001 
ORR HR 3.4 
95 % CI 2.5 – 4.7 
P value  < 0.0001 
OS HR 1.02 
95 % CI 0.68 – 1.54 
P value  0.5394 
Sym Point estimate NR 
95 % CI NR 
P value  < 0.0001 
TDSym HR 0.54 
95 % CI 0.40 – 0.71 
P value  < 0.0001 
HrQoL (Global QoL) Estimated difference 9.84 
95 % CI 5.39 – 14.28 
P value < 0.0001 
ALK … Anaplastic lymphoma kinase; bid … twice daily; CI … Confidence interval; DCR … Disease control rate; DR … Duration 
of response; ECOG … Eastern Cooperative Oncology Group; EORTC … European Organisation for Research and Treatment of 
Cancer; ER … Estrogen-receptor; HR … hazard ratio; HrQoL … Health related quality of life; ITT … Intent -to-treat; 
iv … intravenous; NR … Not re-ported; ORR … Overall response rate; OS … Overall survival; PFS … Progression-free 
survival; PO … Per os; RECIST … Response Evaluation Criteria in Solid Tumors; S … Safety; Sym … Symptoms of lung 
cancer; TDSym … Time to Deterioation in lung cancer symptoms. 
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Table 2: adverse events 
Profile 1007 (NCT 00932893) [19, 34] 
Grade  
(CTC version not reported) Outcome (%) 
Crizotinib  
(n= 172) 
Chemotherapy 
(n=171) 
Any grade Vision disorder 103 (60 %) 16 (9 %) 
Diarrhea 103 (60 %) 33 (19 %) 
Nausea 94 (55 %) 64 (37 %) 
Vomiting 80 (47 %) 30 (18 %) 
Constipation 73 (42 %) 39 (23 %) 
Elevated transaminases 66 (38 %) 25 (15 %) 
Oedema 54 (31 %) 27 (16 %) 
Upper respiratory infection 44 (26 %) 22 (13 %) 
Dysgeusia 44 (26 %) 16 (9 %) 
Dizziness 37 (22 %) 14 (8 %) 
Fatigue 46 (27 %) 57 (33 %) 
Alopecia 14 (8 %) 35 (21 %) 
Dyspnea 23 (13 %) 32 (19 %) 
Rash 15 (9 %) 29 (17 %) 
Grade 3/4 Elevated transaminases 27 (16 %) 4 (2 %) 
Neutropenia 23 (13 %) 33 (19 %) 
Pulmonary embolism 9 (5 %) 3 (2 %) 
Dyspnea 7 (4 %) 5 (3 %) 
Pneumonia 6 (4 %) 3 (2 %) 
Hypokalaemia 6 (4 %) 0 (0 %) 
ECG QTc prolonged 6 (4 %) 0 (0 %)a 
Fatigue 4 (2 %) 7 (4 %) 
Anaemia 4 (2 %) 9 (5 %) 
Constipation 4 (2 %) 0 (0 %) 
WBC decreased 2 (1 %) 8 (5) 
Nausea 2 (1 %) 1 (1 %) 
Vomiting 2 (1 %) 0 (0 %) 
Dizziness 1 (1 %) 0 (0 %) 
Upper respiratory infection 0 (0 %) 1 (1 %) 
Grade 5  
(Deaths attributed to SAE) 
Total  25 (15 %) 7 (4 %) 
Disease progression  14 (8 %) 3 (2 %) 
Treatment-related  3 (2 %) 1 (1 %) 
Arrythmia 1 (1 %) 0 (0 %) 
ILD or pneumonia 2 (1 %) 0 (0 %) 
Sepsis 0 (0 %) 1 (1 %) 
Other causes 8 (5 %) 3 (2 %) 
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Unkown cause 1 (1 %) 0 (0 %) 
Permanent discontinuations  Total  30 (17 %) 23 (13 %) 
Treatment-related 11 (6 %) 17 (10 %) 
a … No on-treatment assessment 
AE … Adverse event; CTC … Common Terminology Criteria; ECG … Electrocardiography; ILD … Interstitial lung disease; 
SAE … Serious adverse event; WBC … White blood cells 
 
The Profile 1007 is an ongoing international, multi-centre, open-label ran-
domised trial (RCT) with 237 recruiting study centres in Europe, North and 
South America, Asia and Australia [19, 34]. Its objective is to investigate the 
efficacy and safety of crizotinib versus standard chemotherapy (pemetrexed 
or docetaxel) in patients with advanced NSCLC with a specific gene profile 
involving the ALK gene. The estimated study completion date was February 
2013, but accordimg to the database ClinicalTrials.gov the trial is still ongo-
ing. This study includes patients with a histologically or cytologically proven 
diagnosis of stage IIIB or stage IV NSCLC, who are tested positive for the 
ALK fusion gene. Furthermore patients have to have disease progression af-
ter only one prior platinum drug based chemotherapy.   
The included patients were about 50 years of age, and more than 90 % had a 
good ECOG status of 0 or 1. The majority of the study population were never 
smokers. A proportion of 52 % were Caucasians and 45 % were Asians.   
173 patients were randomly assigned to the intervention group consisting of 
250 mg crizotinib orally twice daily, and 174 patients were allocated to the 
control arm receiving chemotherapy with either pemetrexed, 500 mg/m2 iv or 
docetaxel, 75 mg/m2 iv. The chemotherapy regimen was given at investiga-
tor’s choice. At baseline there were no statistically significant differences be-
tween the groups in terms of patient characteristics, smoking status and tu-
mour status. 
For the primary endpoint progression free survival (PFS), the interim analysis 
after a median follow-up of about 12 months showed a statistically significant 
improvement for the intervention group as determined per independent radio-
logy review (crizotinib group 7.7 months vs. chemotherapy group 3.0 months; 
HR 0.49 (95 % CI 0.37-0.64; p<0.0001)). In addition, the secondary endpoint 
objective response rate (ORR) was significantly better in the crizotinib group 
(65.3 % vs. 19.5 %; HR 3.4 (95 % CI 2.5-4.7; p<0.0001)), but it was not re-
ported whether these were complete responses (CR) or partial responses (PR). 
Subgroup analyses for PFS showed also a significant benefit of crizotinib for 
most of the investigated subgroups (e.g. Non-Asians, Asians, male, female, 
ECOG 0/1, ECOG 2). No statistically significant improvement in PFS was 
reported for the small subgroups of patients with non-adenocarcinoma and 
patients aged 65 or older. 
At time of the interim analysis about 30 % of all patients had died in either 
group. The median overall survival (OS) was with 20.3 months (crizotinib 
group) vs. 22.8 months (chemotherapy group) similar in both treatment arms, 
but results were still immature and may have been confounded by crossover 
(111 patients of the chemotherapy group crossed over to crizotinib outside 
the Profile 1007 trial).  
Patient reported outcomes were quality of life (QoL), measured by the Eu-
ropean Organisation for Research and Treatment of Cancer (EORTC) ques-
tionnaire QLQ-C30 and QLQ-LC13 and symptoms of lung cancer. In terms 
estimated study 
completion date: 
February 2013,  
but still ongoing 
 
treatment group: 
crizotinib 
 
control group:  
standard chemotherapy 
(pemetrexed or 
docetaxel) 
significantly longer PFS 
 
significantly  
improved ORR 
OS similar,  
but data yet not mature 
QoL and symptoms of 
lung cancer significantly 
better with crizotinib 
Horizon Scanning in Oncology 
12 LBI-HTA | 2013 
of the symptoms, there was a greater improvement from baseline for the cri-
zotinib group in comparison to the chemotherapy group in cough, dyspnea, 
fatigue, alopecia, insomnia, and pain (p<0.0001 for all). Also in global quali-
ty of life and in all of the subdomains except cognitive functioning there was 
a statistically significant benefit for patients treated with crizotinib.  
Permanent study discontinuations and deaths attributed to serious adverse 
events (SAE) occurred more often in the crizotinib group, although the study-
treatment-related discontinuations were more frequent in the chemotherapy 
group (see table 2). 
Vision disorders occurred in 60 % of all patients in the crizotinib group com-
pared to only 9 % in the chemotherapy group. Therefore vision disorders 
were the most common adverse events with crizotinib, none of them being 
grade 3 or 4. 
The number of adverse events of grade 3 or 4 affecting more than 3 % of the 
patients in at least one treatment arm was comparable in both groups. These 
were elevated transaminases, pulmonary embolism, dyspnea, pneumonia, hy-
pokalaemia, prolonged ECG QTc, neutropenia, anaemia, decreased white 
blood cell count, and fatigue.   
The elevated transaminases, pulmonary embolism, dyspnea, pneumonia, 
hypokalaemia, and prolonged ECG QTc occurred more often in the inter-
vention group, while neutropenia, anaemia, decreased white blood cell 
count, and fatigue were more frequent in the control group. 
The investigators of the study concluded that crizotinib has a distinct side 
effect profile when compared with single-agent chemotherapy and is gener-
ally tolerable and manageable. 
 
 
6.2 Efficacy and safety – further studies 
To date the interim results of 2 single-arm open label phase I/II trials inves-
tigating crizotinib for the treatment of patients with ALK-positive advanced 
NSCLC have been published. 
In the first trial (Profile 1001) [23-28, 31] patients with ALK-positive stage III 
or IV NSCLC with only 1 prior chemotherapy treatment (platinum-based) 
receive oral crizotinib 250 mg twice daily in ensuing 28-day cycles. The data 
cut-off for the latest interim analysis of this study was January 2012 [2]. At 
this time 149 patients had been enrolled and 143 were included in the re-
sponse-evaluable population. 
Within this population, 88 achieved an objective response (ORR 61.5 % (95 % 
CI 53.0-69.5)), with three patients having a CR and 85 having a PR. During 
follow up (median 16.6 months) the median PFS was 9.9 months (95 % CI 
7.7-13.4). At this time the median OS was 29.6 months although OS data 
were not mature.  
Overall, 97 % of the patients experienced treatment-related AEs and 24 % of 
them had grade 3-4 AEs [26]. The most common grade 3-4 AEs were neutro-
penia (6 %), raised alanine aminotransferase (4 %), hypophosphataemia (4 %), 
and lymphopenia (4 %). 12.8 % of the patients had AEs that were associated 
with permanent discontinuation from treatment, which was treatment-related 
in 3 patients. One death during the study was attributed to study drug toxicity. 
more permanent study 
discontinuations and 
more death from SAE 
vision disorders:  
most common AEs 
grade 3/4 AEs 
comparable 
single arm open label 
phase I/II trial 
ORR: 61 % 
median PFS about 10 
months 
OS 30 months but  
not mature  
24 % grade 3/4 AEs 
one death from drug 
toxicity 
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The second Phase I/II trial (Profile 1005) investigates crizotinib in patients 
with ALK-positive advanced NSCLC previously treated with at least 1 
chemotherapy regimen [32, 33, 35-39]. All patients receive oral crizotinib 
250 mg twice daily in continuous 3-week cycles.   
The latest interim analysis (cut-off on January 2012) included the safety re-
sults of 901 patients and efficacy results of the population with a centrally con-
firmed ALK FISH test (first 261 patients enrolled and treated in the study) [37]. 
The ORR within the mature population was 59.8 % (95 % CI 53.6-65.9) with 
CR in 4 patients and PR in 151 patients. At the time of analysis there were 
167 PFS events, showing a median PFS of 8.1 months (95 % CI 6.8-9.7).  
Safety results were reported for the overall patient population (n=901) with 
treatment-related AEs in 91.8 %. Treatment-related grade ≥3 AEs were re-
ported in 25.6 % of patients. The most frequently grade 3/4 were neutro-
penia (5.5 %), increased alanine aminotransferase (4.0 %), and fatigue (2.0 %). 
198 deaths occurred during the study period and 4 of them were considered 
treatment-related by the investigators. 
 
 
7 Estimated costs 
In Austria the pharmacy retail price for one package of crizotinib containing 
60 250mg tablets is € 8,340 [40].  However, the reimbursement price paid by 
the statutory health insurance funds is with € 6,089 considerably lower [41]. 
Administered as second line therapy for advanced NSCLC, the recommend-
ed daily dose is 500 mg continuously. This results in costs of about € 200 per 
day equalling € 6,100 per month. 
As crizotinib is only approved for patients with ALK-positive NSCLC, addi-
tional costs of about € 100 per patient for the ALK-testing will be incurred 
[42]. These costs do not account for the high percentage (above 90 %) of 
NSCLC patients with ALK-negative test results. For patients (around 2,900) 
tested in Austria diagnostic costs of 290,000.- would need to be added. 
 
 
8 Ongoing research 
A search in the databases ClinicalTrials.gov and cinicaltrialsregister.eu yielded 3 
further on-going phase III/IV trials investigating crizotinib, besides the Profile 
1007 trial (NCT00932893), of which interim results are presented in this report. 
All of them are conducted in patients with NSCLC: 
NCT01154140: (EudraCT 2010-021336-33): PROFILE 1014 – A parallel open-
label randomized controlled phase III trial, testing the efficacy of crizotinib ver-
sus standard chemotherapy (pemetrexed/cisplatin or carboplatin) in patients 
with ALK positive non squamous cancer of the lung. The estimated study com-
pletion date is December 2013. 
NCT01639001: A cross-over open-label randomized controlled phase III trial of 
crizotinib versus chemotherapy (pemetrexed/cisplatin or pemetrexed/ car-
second single arm open 
label phase I/II trial 
ORR: 60 % 
median PFS about  
8 months 
 
26 % grade 3/4 AEs 
4 treatment-related 
deaths 
monthly costs: € 6,100 
additional costs:  
€ 100 per patient  
for ALK test 
3 further phase III/IV 
trials for NSCLC 
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boplatin) in previously untreated ALK positive East Asian NSCLC patients. The 
estimated study completion date is September 2015. 
NCT01597258: An observational single-arm phase IV trial evaluating the safety 
and efficacy of crizotinib in patients with NSCLC. The study is part of the regu-
latory post marketing commitment plan. The estimated study completion date is 
May 2017. 
In addition there are 6 on-going phase I/II trials for crizotinib alone or in combi-
nation with chemotherapy for patients with NSCLC and 9 on-going phase I/II 
trials investigating crizotinib in advanced cancer patients (various types of can-
cer), patients with anaplastic large cell lymphoma or children with diffuse pon-
tine glioma (DIPG) or high-grade glioma (HGG). 
 
 
9 Commentary 
To date crizotinib is approved by the FDA for treatment of patients with ALK-
positive NSCLC [6]. The approval was based on data of 2 phase I/II single arm 
trials demonstrating a favourable benefit-risk profile for crizotinib when com-
pared to chemotherapeutic agents approved for NSCLC. In Europe this approval 
is restricted only to second line therapy for ALK-positive NSCLC patients with 
disease progression after chemotherapy [2]. Both grantings are contingent upon 
the completion of postmarketing clinical phase III trials to verify and describe the 
clinical benefit of crizotinib [2, 6]. 
For ALK-positive NSCLC, results of 2 single arm phase I/II trials and 1 random-
ized phase III trial were found. Compared to an unselected NSCLC population, 
study participants are relatively young and more likely to be never or light smok-
ers, which seems to be representative for an ALK positive NSCLC population.
  
In the phase III trial (Profile 1007) crizotinib was investigated as second line 
therapy in comparison to standard chemotherapy. Interim results after a median 
follow-up of about 12 months showed statistically significant better PFS (7.7 
months vs. 3.0 months) and ORR (65.3 % vs. 19.5 %) for the crizotinib group. 
The OS rates were comparable in both groups, but the authors mentioned that 
these data were immature at the time of analysis. Furthermore, due to a possible 
confounding by a high cross over rate, it could be generally difficult to determine 
mature overall survival data in this study.  
Improved QoL in favour of crizotinib was found in all domains of the EORTC 
QLQ-C30 and QLQ-LC-13 questionnaires and this improvement was statistically 
significant for all but one (cognitive functioning) domain. Furthermore, there 
was a significant benefit in terms of lung cancer symptoms in the crizotinib 
group. Concerning AEs of higher grade both groups showed quite similar rates of 
about 50 %, with the most common AEs being elevated transaminases (16 %) for 
crizotinib and neutropenia (19 %) for chemotherapy. Although the number of 
overall deaths was comparable in both groups, there was an increased number of 
deaths related to SAEs within the crizotinib group, mostly due to disease progres-
sion. In addition, different types of vision disorders occurred in a higher propor-
tion of patients treated with crizotinib, but all of them seemed to be of lower 
grades. 
6 phase I/II trials  
for NSCLC 
9 phase I/II trials  
for other types of cancer 
contingent approval in 
Europe and USA 
one randomized phase 
III trial for NSCLC 
 
 
 
significantly better than 
chemotherapy in PFS, 
ORR and QoL 
 
no differences in OS and 
higher grade AEs 
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It has to be mentioned that none of the trials investigating crizotinib in NSCLC 
patients has been completed yet and results are only based on interim analyses. 
Furthermore most of them are available as conference posters or oral presenta-
tion slides only, provided by the manufacturer. Especially for the phase III trial 
no publication in a peer review journal is at hand, hence the possibility of bias 
cannot be excluded.  
As the effectiveness of crizotinib is based on the inhibition of ALK, it only affects 
ALK-positive NSCLC patients. Therefore, reliable ALK-testing prior to treat-
ment initiation is crucial for patient selection. At the moment the FISH assay 
used in the phase I/II and phase III trials is the only validated assay for ALK. But 
according to Thunnissen et al. interpretation of the ALK FISH analysis is more 
complex than for other FISH assays (e.g. the fusion inversion occurs in the same 
chromosome arm and the red and green signals may be slightly separated and the 
fusion to yellow flourescence is not apparent) [20]. Because of this, a specific 
training and experience with ALK FISH is needed. Moreover FISH is not feasi-
ble in all laboratories and the results are not always clear. McLeer-Florin et al. 
[43] reported that 19 % of all specimen analyzed by FISH were not interpretable. 
Based on calculations using data of the Profile 1001 trial Chihara et al. suggested 
that a substantial number of patients identified as having ALK rearrangements 
by means of FISH analysis had false positive results [44]. The authors therefore 
concluded that diagnosis using FISH is of limited value. However, the question of 
how best to select patients that may benefit from crizotinib treatment needs to be 
answered. There is evidence that immunohistochemistry IHC could be useful 
and less expensive than FISH and some of the difficulties in interpreting FISH 
results may be alleviated by automated procedures. Anyway, rigorous quality as-
sessment is of maximum importance to ensure reliable results and appropriate 
patient selection [20]. Otherwise there is a potential risk for NSCLC patients to 
be treated with a single agent therapy, that is crizotinib, which is not effective at 
all, thus foregoing other, effective treatment options. 
One of the major limitations of crizotinib is the primary or acquired drug re-
sistance, which has also been observed with other targeted therapies [45]. This 
may be a reason why an increased number of patients died due to disease pro-
gression in the Profile 1007 trial. The mechanisms of drug resistance are under 
investigation in several recent studies. Understanding these specific mechanisms 
may help in the development of effective subsequent clinical treatments. How to 
best treat patients who develop acquired resistance to crizotinib has not been de-
fined yet [45]. Moreover, several clinical trials are planned or under way to evalu-
ate the efficacy of new ALK inhibitors and combination strategies to overcome 
resistance [46]. 
When compared to standard chemotherapy, the costs for crizotinib are rather 
high (about 2 to 4 times higher). For the budget impact, one has to consider, that 
the number of patients suitable for this therapy is small (1 %-7 % of NSCLC), 
but also costs for the ALK testing of all NSCLC patients have to be taken into ac-
count. 
In summary the interim results of one RCT have shown a statistically significant 
benefit of crizotinib over standard chemotherapy in terms of PFS, ORR and QoL, 
with comparable results for OS and AEs of higher grade. Nevertheless these 
seemingly positive results have to be confirmed by the final results of this study 
and further RCTs, as demanded by the European and US regulatory authorities. 
However this therapy option is only suitable for the relatively small group of 
ALK-positive patients, but at least a tenfold of persons have to be tested for the 
ALK gene mutation.  
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NSCLC, only interim 
results 
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